David S. Tierney's most recent trade in Catalyst Pharmaceuticals Inc was a trade of 50,000 Common Stock, par value $0.001 per share done at an average price of $2.2 . Disclosure was reported to the exchange on Aug. 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.24 per share. | 27 Aug 2025 | 50,000 | 405,620 (0%) | 0% | 2.2 | 112,000 | Common Stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 50,000 | 158,274 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 27 Aug 2025 | 26,000 | 379,620 (0%) | 0% | 20.2 | 525,200 | Common Stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 355,620 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 208,274 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 212,274 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 351,620 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,413 | 213,607 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,413 | 350,287 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 23,248 | 212,179 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,841 | 215,020 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 21 Aug 2024 | 15,000 | 363,874 (0%) | 0% | 4.0 | 60,150 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 21 Aug 2024 | 15,000 | 348,874 (0%) | 0% | 20.1 | 301,455 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2024 | 15,000 | 188,931 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 25,000 | 203,931 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 15.68 per share. | 08 Apr 2024 | 25,000 | 348,874 (0%) | 0% | 15.7 | 392,000 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 08 Apr 2024 | 25,000 | 373,874 (0%) | 0% | 4.0 | 100,250 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David Tierney S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 228,931 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | S. David Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 348,874 (0%) | 0% | - | Common Stock, Par Value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Tierney David S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 10,000 | 232,931 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Tierney S. David | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 02 Jan 2024 | 10,000 | 344,874 (0%) | 0% | 1.1 | 11,300 | Common Stock, Par Value $0.001 per share |
| Catalyst Pharmaceuticals Inc | S. David Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 1,333 | 334,874 (0%) | 0% | - | Common Stock, Par Value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | S. Tierney David | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 1,333 | 242,931 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Tierney S. David | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 50,000 | 244,264 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 12 Dec 2023 | 50,000 | 383,541 (0%) | 0% | 1.1 | 56,500 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David Tierney S. | Director | Sale of securities on an exchange or to another person at price $ 13.32 per share. | 12 Dec 2023 | 50,000 | 333,541 (0%) | 0% | 13.3 | 666,250 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 29,524 | 290,024 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Tierney David S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 4,240 | 294,264 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 20,000 | 260,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.79 per share. | 11 May 2023 | 20,000 | 333,541 (0%) | 0% | 0.8 | 15,800 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 05 Apr 2023 | 30,000 | 313,541 (0%) | 0% | 16.8 | 504,900 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 30,000 | 280,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.79 per share. | 05 Apr 2023 | 30,000 | 343,541 (0%) | 0% | 0.8 | 23,700 | Common stock, par value $0.001 per share |
| Zevra Therapeutics Inc | David S. Tierney | Director | Purchase of securities on an exchange or from another person at price $ 4.15 per share. | 09 Mar 2023 | 5,000 | 10,835 (0%) | 0% | 4.1 | 20,732 | Common Stock |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,000 | 313,541 (0%) | 0% | - | Common Stock, Par Value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,000 | 310,500 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 15,000 | 310,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 4,000 | 314,500 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 1,334 | 295,500 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 1,334 | 309,541 (0%) | 0% | - | Common Stock, Par Value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.53 per share. | 22 Aug 2022 | 20,000 | 328,207 (0%) | 0% | 2.5 | 50,600 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2022 | 20,000 | 296,834 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 14.16 per share. | 22 Aug 2022 | 20,000 | 308,207 (0%) | 0% | 14.2 | 283,180 | Common stock, par value $0.001 per share |
| Zevra Therapeutics Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | David S. Tierney | Director | Purchase of securities on an exchange or from another person at price $ 4.39 per share. | 25 May 2022 | 2,000 | 5,835 (0%) | 0% | 4.4 | 8,780 | Common Stock |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 20,000 | 252,333 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 20 May 2022 | 20,000 | 308,207 (0%) | 0% | - | Common stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.53 per share. | 20 May 2022 | 20,000 | 328,207 (0%) | 0% | 2.5 | 50,600 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 12,000 | 336,834 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2021 | 20,000 | 324,834 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 1,333 | 308,207 (0%) | 0% | - | Common Stock, Par Value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 1,333 | 304,834 | - | - | Restricted Stock Units | |
| Zevra Therapeutics Inc | David S. Tierney | Director | Purchase of securities on an exchange or from another person at price $ 7.79 per share. | 30 Nov 2021 | 2,000 | 3,835 (0%) | 0% | 7.8 | 15,578 | Common Stock |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 13 Aug 2021 | 50,000 | 356,874 (0%) | 0% | 3.1 | 156,000 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Sale of securities on an exchange or to another person at price $ 6.08 per share. | 13 Aug 2021 | 50,000 | 306,874 (0%) | 0% | 6.1 | 303,895 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 50,000 | 306,167 | - | - | Options to purchase common stock | |
| Zevra Therapeutics Inc | David S. Tierney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,333 | 326,167 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | David S. Tierney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,333 | 306,874 (0%) | 0% | - | Common Stock, Par Value $0.001 per share |